UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
OCTOBER 17, 2007 (APRIL 19, 2010)
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)
COMPETITIVE TECHNOLOGIES, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE
--------
(STATE OR OTHER JURISDICTION OF INCORPORATION)
1-8696 36-2664428
------ ----------
(COMMISSION FILE NUMBER) (IRS EMPLOYER IDENTIFICATION NO.)
1375 KINGS HIGHWAY EAST, FAIRFIELD, CONNECTICUT 06824
-----------------------------------------------------
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)(ZIP CODE)
(203) 368-6044
--------------
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE:
777 COMMERCE DRIVE, FAIRFIELD, CONNECTICUT 06825
------------------------------------------------
(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
CTTC8k3411001
ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
On October 17, 2007, Competitive Technologies, Inc. (the "Company") entered into
an agreement with Daeyang E&C Co., Ltd., a South Korean corporation. Under the
agreement, the Company granted Daeyang the right to manufacture the Company's
Calmare pain therapy device. The term of the agreement is 10 years, and no
payment other than a $1,000 license fee was due under the agreement until units
are delivered. Daeyang changed its name to GEOMC Co., Ltd. on March 29, 2008.
On August 22, 2008 the Company agreed to grant GEOMC the right to designate the
distributor of the Calmare device in South Korea, subject to the terms and
conditions of the October 17, 2007 agreement.
On January 18, 2010, the Company agreed with GEOMC to a memorandum of
understanding regarding per unit pricing of the Calmare pain therapy device.
On February 4, 2011, the Company agreed to grant GEOMC the right to designate
the distributor of the Calmare device in Japan, subject to the terms and
conditions of the October 17, 2007 agreement.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
The following exhibits are filed herewith:
No. Description
--- -----------
10.1 License Agreement between Competitive Technologies, Inc. and Daeyand E&C
Co., Ltd. (now GEOMC Co., Ltd.), dated September 25, 2007. Pursuant to Rule
24b-2 of the Exchange Act, confidential information has been omitted and
marked as "[Confidential Information Omitted]", and has been filed
separately with the Securities and Exchange Commission pursuant to a
Confidential Treatment Application filed with the Commission.
10.2 Distributor Appointment Agreement between Competitive Technologies, Inc.
and GEOMC Co., Ltd. dated August 22, 2008 granting rights in South Korea.
10.3 Memorandum of understanding between Competitive Technologies, Inc. and
GEOMC Co., Ltd. dated January 18, 2010. Pursuant to Rule 24b-2 of the
Exchange Act, confidential information has been omitted and marked as
"[Confidential Information Omitted]", and has been filed separately with
the Securities and Exchange Commission pursuant to a Confidential Treatment
Application filed with the Commission.
10.4 Distributor Appointment Agreement between Competitive Technologies, Inc.
and GEOMC Co., Ltd. dated February 4, 2011 granting rights in Japan.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
COMPETITIVE TECHNOLOGIES, INC.
(Registrant)
Dated: March 4, 2011 By: /s/ Johnnie D. Johnson
--------------------------
Johnnie D. Johnson
Chief Executive Officer
CTTC8k3411002